摘要
目的评价利奈唑胺治疗革兰氏阳性菌(G+)呼吸机相关性肺炎的疗效及用药安全性。方法将相关肺炎者104例分成观察组50例与对照组54例,观察组静脉滴注600 mg利奈唑胺注射液;对照组静脉滴注1.0 g万古霉素注射液,均为1次/12 h。观察两组病人的临床疗效、机械通气时间、G+菌清除率以及药物不良反应等。结果观察组与对照组总有效率(52.0%,37%)、病死率(28.0%,44.4%)、G+菌清除率为(72.0%,55.6%)、机械通气时间短、副作用少,差异显著(P<0.05),均有统计学意义。结论采用抗菌药物利奈唑胺治疗革兰氏阳性菌呼吸机相关性肺炎的临床疗效显著,且安全可靠,值得临床推广应用。
Objective To evaluation using linezolid in the treatment of Gram - positive bacteria(G + ) of ventilator-associated pneumonia the clinical efficacy and safety of medication.Methods 104 cases related pneumonia is divided into the observation group(50 cases) and control group(54 cases).In observation group, intravenous infusion of 600 mg linezolid injection;the control group 1 g injection intravenous vancomycin,are 1/12 h.Observation of the clinical curative effect of two groups of patients,the duration of mechanical ventilation,G + bacteria clearance and drug adverse reaction.Results The observation and control groups total effective rate was (52%,37%),fatality rate was(28%,44.4%),G + bacteria clearance rate was a(72%,55.6%),the mechanical ventilation time was less than the control group,the side effects was lower than the control group,significant difference(P<0.05).Conclusion The antibiotic linezolid in the treatment of Gram - positive bacteria of ventilator associated pneumonia in clinical curative effect,safety and reliability,it is worthy of clinical application.
出处
《生物医学工程学进展》
CAS
2012年第1期60-62,共3页
Progress in Biomedical Engineering
